Vericiguat

Vericiguat
Clinical data
Trade namesVerquvo
License data
Pregnancy
category
Routes of
administration		By mouth
Drug classSoluble guanylate cyclase activator
ATC code
Legal status
Legal status
Identifiers
IUPAC name
  • methyl N-[4,6-diamino-2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]carbamate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
ECHA InfoCard100.247.370
Edit this at Wikidata
Chemical and physical data
FormulaC19H16F2N8O2
Molar mass426.388 g·mol−1
3D model (JSmol)
SMILES
  • COC(=O)NC1=C(N=C(N=C1N)C2=NN(C3=C2C=C(C=N3)F)CC4=CC=CC=C4F)N
InChI
  • InChI=1S/C19H16F2N8O2/c1-31-19(30)25-14-15(22)26-17(27-16(14)23)13-11-6-10(20)7-24-18(11)29(28-13)8-9-4-2-3-5-12(9)21/h2-7H,8H2,1H3,(H,25,30)(H4,22,23,26,27)
  • Key:QZFHIXARHDBPBY-UHFFFAOYSA-N

Vericiguat, sold under the brand name Verquvo, is a medication used to reduce the risk of cardiovascular death and heart failure.[2][3][4] It is taken by mouth.[2][3][4]

Common side effects include low blood pressure and low red cell count (anemia).[3][4]

Vericiguat is a soluble guanylate cyclase (sGC) stimulator.[2] It was approved for medical use in the United States in January 2021,[3][5] and for use in the European Union in July 2021.[4]

Medical uses

Vericiguat is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.[2][3]

Adverse effects

Vericiguat causes harm to the unborn baby and should not be given to pregnant women.[3]

History

The U.S. Food and Drug Administration (FDA) approved vericiguat based on evidence from a clinical trial (NCT02861534) which consisted of 5,050 participants aged 23 to 98 years old with worsening heart failure.[3] The trial was conducted at 694 sites in 42 countries in Europe, Asia, North and South America.[3] The trial enrolled participants with symptoms of worsening heart failure.[3] Participants were randomly assigned to receive vericiguat or a placebo pill once a day.[3] Neither the participants nor the health care professionals knew if the participants were given vericiguat or placebo pill until after the trial was complete.[3]

Society and culture

On 20 May 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for vericiguat, intended for the treatment of symptomatic chronic heart failure in adults with reduced ejection fraction.[6] The applicant for this medicinal product is Bayer AG. Vericiguat was approved for medical use in the European Union in July 2021.[4]

References

  1. 1 2 "Verquvo". Therapeutic Goods Administration (TGA). 29 November 2021. Retrieved 28 December 2021.
  2. 1 2 3 4 5 6 "Verquvo- vericiguat tablet, film coated". DailyMed. Retrieved 9 February 2021.
  3. 1 2 3 4 5 6 7 8 9 10 11 12 "Drug Trials Snapshot: Verquvo". U.S. Food and Drug Administration (FDA). 8 February 2021. Retrieved 8 February 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  4. 1 2 3 4 5 6 "Verquvo EPAR". European Medicines Agency (EMA). 19 May 2021. Retrieved 14 September 2021.
  5. ↑ "Drug Approval Package: Verquvo". U.S. Food and Drug Administration (FDA). 17 February 2021. Retrieved 14 September 2021.
  6. ↑ "Verquvo: Pending EC decision". European Medicines Agency. 20 May 2021. Retrieved 23 May 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

Further reading

  • "Vericiguat". Drug Information Portal. U.S. National Library of Medicine.
  • Clinical trial number NCT02861534 for "A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001) (VICTORIA)" at ClinicalTrials.gov
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.